Formulation of Gamma-Oryzanol Encapsulated Nanoparticles and Their Modulation Effects on Inducible Nitric Oxide Synthase and Nitric Oxide in LPS-Stimulated RAW 264.7 Macrophages
Pharmaceutics · 14.03.2026 · 18 (3) · 365
DOI: 10.3390/pharmaceutics18030365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 14.03.2026. Verfasst von Kornvipa Settakorn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Fund 2024, Chiang Mai University, Fundamental Fund 2026, Chiang Mai University.
Abstract (Originalsprache)
Background/Objectives: Gamma-oryzanol (ORZ), a bioactive compound extracted from rice bran oil, has health-promoting properties but limited therapeutic use due to poor stability and bioavailability. This study aimed to synthesize gamma-oryzanol-encapsulated nanoparticles (ORZ-NPs) and investigate their anti-inflammatory effects in lipopolysaccharide-stimulated RAW 264.7 macrophages.
Methods
ORZ-NPs were synthesized via nanoprecipitation and characterized by dynamic light scattering and transmission electron microscopy. ORZ content was assessed using high performance liquid chromatography. In vitro release was determined using a dialysis method. Inducible nitric oxide synthase (iNOS) was assessed by Western blotting, nitric oxide (NO) by Griess assay, and tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay.
Results
ORZ-NPs exhibited spherical morphology with a mean particle size of 93.320 ± 2.027 nm, polydispersity index 0.149 ± 0.025, and zeta potential −22.400 ± 0.252 mV. ORZ remained stable for 90 days. In vitro release reached 70% at 24 h in PBS (pH 7.4). At 50 μg mL−1, ORZ-NPs significantly decreased iNOS and NO production (approximately 65% of control, p < 0.01), without affecting TNF-α or IL-6.
Conclusions
ORZ-NPs demonstrate selective anti-inflammatory activities by suppressing iNOS and NO production while pro-inflammatory cytokines remain unaffected. These findings suggest a partial modulatory effect on the inflammatory signaling pathway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
- Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.
ORCID-Profile: Kornvipa Settakorn, Chuda Chittasupho, Weerasak Samee, Mingkwan Na Takuathung
Förderung
- Fundamental Fund 2024, Chiang Mai University
- Fundamental Fund 2026
- Chiang Mai University
- Thailand Science Research and Innovation
Zitieren
APA
Settakorn, K., Chittasupho, C., Samee, W., Koonrungsesomboon, N., & Takuathung, M. N. (2026). Formulation of Gamma-Oryzanol Encapsulated Nanoparticles and Their Modulation Effects on Inducible Nitric Oxide Synthase and Nitric Oxide in LPS-Stimulated RAW 264.7 Macrophages. Pharmaceutics, 18(3), 365. https://doi.org/10.3390/pharmaceutics18030365
Vancouver
Settakorn K, Chittasupho C, Samee W, Koonrungsesomboon N, Takuathung MN. Formulation of Gamma-Oryzanol Encapsulated Nanoparticles and Their Modulation Effects on Inducible Nitric Oxide Synthase and Nitric Oxide in LPS-Stimulated RAW 264.7 Macrophages. Pharmaceutics. 2026;18(3):365. doi:10.3390/pharmaceutics18030365
BibTeX
@article{Settakorn2026,
author = {Settakorn, Kornvipa and Chittasupho, Chuda and Samee, Weerasak and Koonrungsesomboon, Nut and Takuathung, Mingkwan Na},
title = {Formulation of Gamma-Oryzanol Encapsulated Nanoparticles and Their Modulation Effects on Inducible Nitric Oxide Synthase and Nitric Oxide in LPS-Stimulated RAW 264.7 Macrophages},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {3},
pages = {365},
doi = {10.3390/pharmaceutics18030365}
}
EUVIMED